# **Metabolic Resurrection: The P7C3-A20 Paradigm and the Reversal of Advanced Alzheimer’s Pathology via NAD+ Homeostasis**

## **1\. Introduction: The Stagnation of Alzheimer’s Therapeutics and the Metabolic Pivot**

### **1.1 The Historical Context of Irreversibility**

For over a century, since Alois Alzheimer first described the presenile dementia that bears his name, the clinical and scientific consensus has characterized Alzheimer’s disease (AD) as a relentless, unidirectional vector of degeneration. The prevailing dogma posited that once the neuroarchitectural integrity of the brain was compromised—manifesting as synaptic loss, neuronal death, and gross atrophy—restoration of function was biologically impossible.1 Consequently, the global pharmaceutical strategy has been almost exclusively defensive, focusing on prevention in at-risk cohorts or the deceleration of decline in early-stage patients.

This defensive posture was largely driven by the Amyloid Cascade Hypothesis, which identified the accumulation of amyloid-beta (Aβ) plaques as the varying precipitating event in AD pathology. However, the subsequent decades of clinical trials targeting amyloid clearance have yielded outcomes that are statistically significant yet clinically marginal, often slowing cognitive decline by mere percentage points without arresting the disease or restoring lost faculties.3 This stagnation has necessitated a fundamental re-evaluation of the disease etiology, shifting the focus from protein aggregation to bioenergetic failure.

### **1.2 The Bioenergetic Hypothesis: "Type 3 Diabetes"**

Emerging concurrently with the failures of amyloid-centric therapies is the conceptualization of AD as a metabolic disorder, frequently colloquially termed "Type 3 Diabetes." This paradigm suggests that the upstream driver of neurodegeneration is not the plaque itself, but the brain’s inability to metabolize glucose and generate adenosine triphosphate (ATP) effectively. The brain, while constituting only 2% of total body mass, consumes approximately 20% of the body’s basal energy. Neurons are obligate aerobes with massive metabolic demands required to maintain ionic gradients via the Na+/K+ ATPase pump, support axonal transport, and facilitate synaptic transmission.4

In this context, the accumulation of amyloid and tau can be viewed as downstream consequences of a bioenergetic crisis. When neurons lack the energy to drive proteasomal clearance and autophagy, misfolded proteins accumulate. When they lack the energy to repair DNA damage, genomic instability ensues. This bioenergetic perspective identifies the depletion of Nicotinamide Adenine Dinucleotide (NAD+) as a critical, proximal cause of AD pathology.1 NAD+ is the central coenzyme of cellular metabolism, essential for the conversion of nutrients into energy and for the activation of enzymes that maintain cellular health.

### **1.3 The 2025 Breakthrough: Reversal vs. Prevention**

In December 2025, a landmark study published in *Cell Reports Medicine* by a collaborative team from Case Western Reserve University, University Hospitals, and the Louis Stokes Cleveland VA Medical Center challenged the century-old dogma of irreversibility. Led by Dr. Kalyani Chaubey and senior author Dr. Andrew Pieper, the research demonstrated that restoring brain NAD+ balance could not only prevent AD but *reverse* advanced pathology and restore full cognitive function in murine models.1

The study utilized a specific pharmacologic agent, P7C3-A20, to potentiate the intrinsic NAD+ salvage pathway within the brain. The results were profound: mice with established, advanced AD pathology—comparable to mid-to-late stage human dementia—exhibited complete restoration of spatial memory, repair of the blood-brain barrier (BBB), and normalization of inflammatory markers.1 This report provides an exhaustive analysis of these findings, the biochemical mechanisms of P7C3-A20, the comparative landscape of NAD+ therapeutics, and the translational path toward human application.

## **2\. The Preclinical Evidence: Reversing Advanced Pathology**

The Chaubey and Pieper study is distinguished not merely by its positive results, but by the rigor of its experimental design regarding disease staging. Most preclinical AD studies intervene during the "prodromal" phase (before symptoms appear) to test prevention. This study specifically targeted the "advanced" phase, where pathology and cognitive deficits were already entrenched, making the observed recovery a true reversal of the disease state.1

### **2.1 The Murine Models of Alzheimer's Disease**

To ensure the robustness of their findings, the researchers employed two distinct transgenic mouse models, each recapitulating different aspects of human AD pathology. This dual-model approach addresses a common criticism in AD research regarding the translatability of mouse data to humans.3

| Mouse Model | Genetic Driver | Pathological Features | Human Equivalent |
| :---- | :---- | :---- | :---- |
| **5xFAD** | Overexpression of human APP and PSEN1 with five familial AD mutations | Rapid, aggressive amyloid plaque accumulation; gliosis; neurodegeneration | Familial (early-onset) AD with heavy amyloid burden |
| **PS19** | Expression of human Tau-P301S mutation | Neurofibrillary tangles; synaptic loss; brain atrophy; neuronal death | Tauopathy; Frontotemporal Dementia; AD-related tau pathology |

The use of both 5xFAD (amyloid-driven) and PS19 (tau-driven) models demonstrates that the metabolic intervention targets a fundamental mechanism common to proteotoxicity, regardless of the specific aggregating protein.1

### **2.2 Therapeutic Intervention Protocol**

The experimental protocol was designed to mimic a clinical scenario where a patient presents with established dementia.

* **Start of Treatment:** The intervention began when the mice were six months old. In these aggressive models, six months represents a stage of significant disease progression, characterized by established plaques/tangles, measurable cognitive decline, and BBB leakage.1  
* **Duration:** The mice received daily injections of P7C3-A20 for six months, concluding at one year of age.6  
* **Compound:** P7C3-A20, a highly active variant of the P7C3 aminopropyl carbazole class, was selected for its ability to enhance NAD+ salvage without inducing supraphysiologic toxicity.2

### **2.3 Structural and Histological Recovery**

The post-mortem analysis of the treated brains revealed comprehensive structural repair, challenging the notion that neurodegeneration leads to permanent scarring and tissue loss.

#### **2.3.1 Blood-Brain Barrier (BBB) Repair**

One of the earliest and most consequential pathologies in AD is the breakdown of the BBB. The BBB is a selective semi-permeable border formed by endothelial cells, pericytes, and astrocytic end-feet. In AD, pericytes degenerate, leading to "leaks" that allow neurotoxic blood proteins (such as fibrinogen) and immune cells to infiltrate the brain parenchyma, triggering chronic neuroinflammation.6  
The study utilized electron microscopy to visualize the BBB ultrastructure. The results showed that P7C3-A20 treatment:

* **Sealed Endothelial Gaps:** The physical leaks in the barrier were closed.  
* Restored Pericyte Health: Pericytes, which are highly sensitive to metabolic stress, were regenerated or preserved, restoring their coverage of the capillaries.  
  This repair is critical because a leaky BBB creates a toxic environment that precludes neuronal recovery; by sealing the barrier, P7C3-A20 re-established the protected environment necessary for synaptic plasticity.6

#### **2.3.2 Clearance of Biomarkers (p-tau217)**

While the snippets do not explicitly claim the total eradication of all amyloid plaques, they highlight a significant normalization of pathological biomarkers. Most notably, the treatment reduced blood levels of **phosphorylated tau 217 (p-tau217)**.1

* **Significance:** p-tau217 is currently considered one of the most specific and sensitive fluid biomarkers for Alzheimer's disease in humans, correlating strongly with amyloid and tau burden in the brain.  
* **Outcome:** The reduction of p-tau217 to levels comparable to healthy wild-type mice provides objective, biochemical evidence of disease modification and suggests that the neurodegenerative process driving tau phosphorylation was halted and reversed.6

#### **2.3.3 Proteomic Normalization**

The research team conducted a broad proteomic analysis, screening thousands of proteins in the brain. They identified a cluster of **46 specific proteins** that were dysregulated in both human AD brains and the untreated AD mice. Treatment with P7C3-A20 returned the expression levels of these proteins to the baseline seen in healthy controls. These proteins are primarily involved in synaptic transmission, mitochondrial function, and waste management, providing a molecular fingerprint of the recovery.6

### **2.4 Functional Recovery: Memory and Motor Coordination**

The ultimate test of any AD therapy is the restoration of function. Structural repair is meaningless without cognitive improvement. The study employed rigorous behavioral assays to quantify this recovery.

#### **2.4.1 Spatial Memory: The Morris Water Maze**

The Morris Water Maze is the gold standard for assessing hippocampal-dependent spatial learning and memory in rodents. Mice are placed in a pool of opaque water and must navigate to a submerged, invisible platform using distal visual cues.

* **Untreated AD Mice:** Typically wander aimlessly or take significantly longer to find the platform, indicating a failure of spatial mapping and memory recall.  
* **P7C3-A20 Treated Mice:** Demonstrated a complete recovery of spatial memory. Their latency to find the platform and their path efficiency were statistically indistinguishable from healthy, age-matched wild-type mice.6  
* **Implication:** This suggests that the neural circuits encoding space and memory were not irrevocably destroyed but were functionally dormant due to metabolic starvation. Once energy balance was restored, these circuits reactivated.

#### **2.4.2 Motor Learning: The Rotarod Test**

To assess motor coordination and cerebellar function—which are often compromised in advanced tauopathies—the researchers used the Rotarod test. Mice are placed on a rotating cylinder that accelerates; the time they remain on the rod before falling is measured.

* **Observation:** Advanced-stage mice treated with P7C3-A20 regained their ability to balance and coordinate movement, performing at healthy baseline levels.6 This indicates a widespread neuroprotective effect extending beyond the hippocampus to motor systems.

## **3\. The Therapeutic Agent: P7C3-A20**

To understand the efficacy of the intervention, it is necessary to examine the history, chemistry, and pharmacological profile of the P7C3 class of compounds.

### **3.1 Origin and Discovery Screen**

The P7C3 compound series was discovered in a phenotypic screen conducted by Dr. Andrew Pieper and Dr. Steven McKnight at UT Southwestern Medical Center (later moving to Case Western and University of Iowa). The screen was "target-agnostic," meaning the researchers were not looking for a molecule that hit a specific receptor (like an amyloid inhibitor). Instead, they screened 1,000 drug-like chemicals for their ability to enhance **hippocampal neurogenesis** (the birth of new neurons) in adult mice.10

The lead compound, P7C3 (an aminopropyl carbazole), was identified for its potent ability to protect newborn neurons from apoptosis (cell death). In the rigorous environment of the adult hippocampus, most newborn neurons die before they can mature and integrate into circuits. P7C3 promoted their survival, thereby enhancing the net magnitude of neurogenesis.12

### **3.2 Optimization: From P7C3 to P7C3-A20**

Subsequent medicinal chemistry efforts sought to optimize the original molecule for better blood-brain barrier penetration, metabolic stability, and potency.

* **P7C3-A20:** This specific derivative (often referred to as A20) emerged as a lead candidate. It possesses favorable pharmacokinetics, allowing for oral or systemic administration with high CNS penetrance.8  
* **Safety Profile:** Extensive toxicity studies in mice and rats indicated that P7C3 compounds are non-toxic, even at high doses. They do not appear to interact promiscuously with other receptors, which is a common source of side effects in CNS drugs.12

### **3.3 Commercial History and Calico**

The potential of P7C3 led to a high-profile licensing deal in 2014 with Calico (California Life Company), the longevity biotechnology company backed by Google (Alphabet). Calico licensed the P7C3 technology from 2M Companies (who held the license from UT Southwestern) to develop it for neurodegenerative diseases like ALS and Parkinson's.11  
While the specific outcomes of the Calico collaboration were not publicly detailed in the snippets (and the license appears to have concluded or transferred, given the current commercialization by Glengary Brain Health), this early industry interest validates the compound's potential. Currently, the technology is being advanced by Glengary Brain Health, a company co-founded by Dr. Pieper to shepherd the drug through clinical trials.1

## **4\. Mechanisms of Action: The NAD+ Engine**

The core finding of the Chaubey and Pieper study is that P7C3-A20 exerts its neuroprotective effects by restoring the levels of Nicotinamide Adenine Dinucleotide (NAD+). To appreciate this, one must delve into the biochemistry of neuroenergetics.

### **4.1 NAD+: The Central Metabolite**

NAD+ is a coenzyme found in all living cells. It exists in an oxidized form (NAD+) and a reduced form (NADH). Its functions are twofold and vital:

1. **Redox Cofactor:** It accepts electrons during glycolysis and the Citric Acid (Krebs) Cycle, becoming NADH. It then donates these electrons to the Electron Transport Chain (ETC) in mitochondria to generate ATP. Without NAD+, cellular respiration ceases, and the cell dies of energy failure.16  
2. **Enzymatic Substrate:** NAD+ is consumed (destroyed) by enzymes that regulate cellular signaling and repair. The three major classes of NAD+-consuming enzymes are:  
   * **Sirtuins (SIRTs):** Deacetylases that regulate gene expression, inflammation, and mitochondrial biogenesis. SIRT1 and SIRT3 are critical for neuronal stress resistance.4  
   * **PARPs (Poly ADP-ribose polymerases):** Enzymes that detect DNA damage. PARP1 consumes massive amounts of NAD+ to signal DNA repair mechanisms.16  
   * **CD38:** An ectoenzyme involved in calcium signaling and inflammation.16

### **4.2 The Vicious Cycle of NAD+ Depletion in Alzheimer's**

In healthy youth, NAD+ synthesis balances consumption. In aging and AD, this balance collapses due to a "double hit":

* **Decreased Synthesis:** The enzymes responsible for making NAD+ (like NAMPT) decline in efficiency and expression.1  
* **Increased Consumption:** Accumulated DNA damage (from oxidative stress) triggers chronic PARP activation. Similarly, chronic inflammation upregulates CD38. These enzymes devour the intracellular pool of NAD+.4  
* **The Result:** Neurons enter a state of "pseudohypoxia." Despite the presence of oxygen, they lack the NAD+ required to process it. Mitochondria fail, DNA repair stops (leading to more damage and more PARP activation), and the cell eventually undergoes bioenergetic collapse.17

### **4.3 P7C3-A20 as a NAMPT Potentiator**

The primary mechanism by which P7C3-A20 reverses this state is by enhancing the activity of **Nicotinamide Phosphoribosyltransferase (NAMPT)**.

* **The Salvage Pathway:** Neurons rely heavily on the "Salvage Pathway" to maintain NAD+. This pathway recycles Nicotinamide (NAM)—the waste product left after Sirtuins or PARPs use NAD+—back into Nicotinamide Mononucleotide (NMN), which is then converted back to NAD+.  
* **Rate-Limiting Step:** NAMPT is the enzyme that converts NAM to NMN. It is the bottleneck of the entire cycle.  
* **Potentiation:** P7C3-A20 acts as a small-molecule activator (or positive allosteric modulator) of NAMPT. By binding to the enzyme, it increases its catalytic efficiency, allowing the cell to recycle NAM into NAD+ much faster.10

This mechanism is elegant because it relies on the cell's existing infrastructure. It does not force the cell to make NAD+ indefinitely; it simply unclogs the bottleneck, allowing the cell to restore homeostasis based on its own supply of Nicotinamide.

### **4.4 The Mechanistic Controversy: Activator vs. Modulator**

It is important to note a scientific debate regarding the precise biophysical interaction between P7C3 and NAMPT, which adds nuance to the mechanism.

* **The Direct Activation Model:** The initial 2014 study by Wang et al. provided evidence that P7C3 binds directly to NAMPT and increases its activity in biochemical assays.10  
* **The Rear Channel Hypothesis:** Later studies by other groups (e.g., using crystallography) suggested that P7C3 might bind to a "rear channel" of the enzyme or questioned the magnitude of activation in cell-free systems compared to other activators like SBI-797812.18 Some researchers argue that P7C3 acts more as a stabilizer of the enzyme or modulates its feedback inhibition by NAD+.  
* **Functional Consensus:** Despite the crystallographic disputes, the *functional* outcome is undisputed in the literature: P7C3-A20 treatment leads to a measurable and robust increase in intracellular NAD+ levels in stressed cells, protecting them from death.10 The biological reality of survival and NAD+ elevation holds true regardless of the debate over the exact binding pocket.

## **5\. Downstream Effectors: How NAD+ Fixes Memory**

Restoring NAD+ is the "fuel," but how does this fuel translate into retrieved memories and repaired synapses? The research highlights several downstream pathways activated by this metabolic restoration.

### **5.1 The EVA1C and Splicing Connection**

A critical and novel insight from recent research involves **RNA splicing**.

* **Splicing Failure:** AD brains are characterized by widespread errors in RNA splicing, leading to defective proteins that cannot maintain synaptic function.  
* **EVA1C:** The study identified the protein **EVA1C** as a key player. NAD+ levels regulate the expression and function of EVA1C.  
* **Mechanism:** When NAD+ is restored, EVA1C is upregulated. EVA1C then interacts with the cellular splicing machinery to correct the "editing" of genetic instructions. This "splice-switching" capability ensures that neurons produce the correct versions of proteins required for synaptic plasticity and memory.22  
* **Dependency:** Crucially, the researchers found that if they genetically knocked down *Eva1c* in the hippocampus, the memory-enhancing effects of NAD+ were abolished. This proves that EVA1C is an essential conduit through which metabolic health translates to cognitive function.22

### **5.2 Mitochondrial Dynamics: Fission vs. Fusion**

Mitochondria are dynamic organelles that constantly fuse (join together) and undergo fission (split apart).

* **Pathology:** In AD and TBI, oxidative stress drives excessive **mitochondrial fission**. The mitochondria fragment into small, inefficient pieces that cannot generate sufficient ATP or buffer calcium. These fragments release Reactive Oxygen Species (ROS), causing further damage.24  
* **Restoration:** P7C3-A20 treatment inhibits this pathological fission. By restoring NAD+, it activates Sirtuins (likely SIRT1/SIRT3), which regulate mitochondrial dynamics. This preserves the mitochondrial network, allowing energy to be efficiently transported down the long axons of neurons to the synapses, where it is needed for neurotransmission.4

### **5.3 Neuroinflammation and Glial States**

NAD+ restoration also fundamentally alters the immune landscape of the brain.

* **Microglia:** In AD, microglia (immune cells) become chronically activated (pro-inflammatory), attacking neurons and failing to clear plaques. NAD+ restoration shifts microglia from this destructive state to a reparative, phagocytic state (often termed M2-like), facilitating the clearance of debris without damaging healthy tissue.21  
* **Astrocytes:** Metabolic support helps astrocytes maintain glutamate homeostasis, preventing excitotoxicity.5

## **6\. Comparative Therapeutics: P7C3-A20 vs. NMN and NR**

A question naturally arises for patients and clinicians: If NAD+ is the cure, why wait for a new drug? Why not take over-the-counter NAD+ precursors like Nicotinamide Riboside (NR) or Nicotinamide Mononucleotide (NMN)?

The report distinguishes P7C3-A20 from these supplements based on mechanism, bioavailability, and safety.

### **6.1 Bioavailability and Pharmacokinetics**

* **NMN/NR Limitations:** While NMN and NR are popular supplements, their pharmacokinetic profile is complex. When ingested orally, they are often rapidly metabolized by the liver and gut microbiome into Nicotinamide (NAM) before they can enter the bloodstream. Furthermore, transporting intact NMN/NR across the Blood-Brain Barrier (BBB) is inefficient.27  
* **P7C3-A20 Advantage:** P7C3-A20 is a small, lipophilic molecule designed to cross the BBB with high efficiency. Once inside the brain, it works on the *enzyme* (NAMPT) that is already present in the neurons. It essentially "tune-ups" the brain's own machinery to make NAD+ from the available Nicotinamide, rather than trying to force-feed the brain with precursors that may not reach their target.12

### **6.2 The "Supraphysiologic" Risk and Cancer**

Dr. Pieper emphasizes a critical safety distinction: the risk of "supraphysiologic" NAD+ levels.3

* **Unregulated Synthesis:** Direct precursors (NMN/NR) function as raw substrate. High doses can theoretically drive NAD+ levels far above the normal physiological range.  
* **The Cancer Connection:** Cancer cells are metabolically voracious. They hijack the NAD+ salvage pathway (often overexpressing NAMPT) to fuel their rapid division and resist chemotherapy.29 There is a legitimate concern in the oncology community that unregulated NAD+ supplementation could act as "fertilizer" for latent tumors, particularly glioblastomas or undiagnosed metastases.29  
* **The P7C3 Solution:** P7C3-A20 acts as a modulator, not a fuel source. Because it potentiates the enzyme rather than providing the substrate, the cell's natural feedback loops (e.g., feedback inhibition of NAMPT by high NAD+) likely remain intact. This suggests that P7C3 can restore NAD+ to *youthful, homeostatic* levels without pushing them into the dangerous "supraphysiologic" zone that might favor tumorigenesis.6 This "metabolic balance" approach is framed as a safer long-term strategy for an elderly population with higher baseline cancer risks.

### **6.3 Clinical Trial Efficacy Comparison**

* **NMN/NR in Humans:** Clinical trials of NR and NMN have shown they can safely raise blood NAD+ levels. However, evidence for cognitive improvement in AD has been mixed or modest. For example, a trial of NR in Mild Cognitive Impairment (MCI) showed some changes in cerebral blood flow but failed to show significant memory improvements in the short term.28  
* **P7C3-A20 Potential:** The profound reversal seen in the mouse models—specifically the structural repair of the BBB and clearance of p-tau217—suggests that the intracellular potentiation achieved by P7C3 might be more biologically potent in the CNS than systemic supplementation.1

| Feature | P7C3-A20 (NAMPT Potentiator) | NMN / NR (Precursors) |
| :---- | :---- | :---- |
| **Mechanism** | Enhances intrinsic enzymatic activity (Salvage pathway) | Provides raw substrate for NAD+ synthesis |
| **Regulation** | Subject to intracellular feedback/rate-limiting | Can bypass some rate-limiting steps (dose-dependent) |
| **NAD+ Levels** | Restores to homeostatic/youthful baseline | Can spike to supraphysiologic levels |
| **Bioavailability** | High BBB penetration; lipophilic | Variable; often metabolized in gut/liver |
| **Cancer Risk** | Theoretically lower (regulated limits) | Theoretically higher (fuel for tumor metabolism) |
| **Human Efficacy** | Preclinical (Human trials upcoming) | Mixed (Some biomarkers, limited cognitive data) |

## **7\. Broader Implications: A Pan-Neuroprotective Mechanism?**

The utility of P7C3-A20 extends beyond Alzheimer's Disease. The mechanism of preserving mitochondrial function and NAD+ homeostasis appears to be a fundamental requirement for neuronal survival across various injuries and diseases.

### **7.1 Traumatic Brain Injury (TBI)**

Pieper’s laboratory previously demonstrated that P7C3-A20 could block the chronic neurodegeneration associated with Traumatic Brain Injury (TBI).

* **TBI Pathology:** TBI triggers an acute energy crisis and axonal shearing, leading to a secondary wave of degeneration that can continue for years (CTE).  
* **Efficacy:** Treatment with P7C3-A20 after injury prevented the death of neurons and preserved axonal integrity in mice, effectively stopping the progression from acute injury to chronic dementia.8  
* **Commonality:** The success in both AD and TBI suggests that "energy failure" is the common denominator in neuronal death, whether the trigger is a physical blow or a genetic mutation.

### **7.2 ALS (Amyotrophic Lateral Sclerosis)**

The snippets reference the **MICABO-ALS** trial (NCT04244630), which investigates "Mitochondrial Capacity Boost" in ALS patients.35 While this specific trial uses a cocktail of antioxidants and precursors (not P7C3), it validates the target.

* **P7C3 in ALS:** Previous studies (including those under the Calico license) showed that P7C3 compounds protected motor neurons in the SOD1-G93A mouse model of ALS, preserving muscle function and extending lifespan.11 This reinforces the compound's potential as a broad-spectrum neuroprotective agent.

### **7.3 Glaucoma and Optic Nerve Injury**

The optic nerve is a pure white matter tract and a part of the CNS. In models of optic nerve crush (mimicking glaucoma or trauma), P7C3-A20 prevented the death of retinal ganglion cells.37 This further supports its ability to protect neurons under severe stress.

## **8\. Clinical Translation: The Path to Human Trials**

The transition from successful mouse studies to human medicine is the most challenging phase of drug development. However, the roadmap for P7C3-A20 is clearly defined.

### **8.1 Commercialization: Glengary Brain Health**

The development of P7C3-A20 is being managed by **Glengary Brain Health**, a Cleveland-based biotechnology company co-founded by Dr. Andrew Pieper. This commercial entity acts as the vehicle to secure funding, manage intellectual property, and interface with the FDA.1

* **Funding:** The research has been supported by significant grants, including from the **Harrington Discovery Institute**, which specializes in bridging the gap between academic discovery and clinical application.1

### **8.2 Trial Design and Biomarkers**

A major advantage for future P7C3 trials is the validation of **p-tau217** as a biomarker in the mouse study.

* **The Biomarker Problem:** Historically, AD trials required years of observation to see if a drug slowed memory decline. This made trials expensive and slow.  
* **The Solution:** The study showed that P7C3-A20 reduced blood levels of p-tau217 in mice.1 Since p-tau217 is now an FDA-cleared biomarker for humans, Glengary Brain Health can design Phase 2 trials that use blood p-tau217 reduction as a surrogate endpoint. This allows for a rapid "go/no-go" decision on whether the drug is working biologically in patients, potentially years before cognitive benefits are statistically confirmed.

### **8.3 The "Valley of Death"**

Despite the promise, the "Valley of Death"—the gap between preclinical success and approved therapy—is littered with Alzheimer's drugs that worked in mice (particularly 5xFAD mice) but failed in humans.

* **Caveats:** Mice do not live long enough to develop the vascular comorbidities (hypertension, diabetes) that complicate human AD. Furthermore, the 5xFAD model is an aggressive familial model, whereas most human cases are sporadic.  
* **Optimism:** However, the fact that P7C3 worked in *two* distinct models (amyloid and tau) and reversed *advanced* disease gives it a higher probability of success than agents that only worked in prevention models.8

## **9\. Conclusion**

The research led by Dr. Kalyani Chaubey and Dr. Andrew Pieper represents a potential paradigm shift in the treatment of Alzheimer's Disease. By moving beyond the Amyloid Cascade Hypothesis and targeting the fundamental metabolic machinery of the neuron, they have achieved what was previously thought impossible: the reversal of advanced neurodegeneration in animal models.

The identification of NAD+ depletion as a critical upstream failure mode integrates diverse pathologies—mitochondrial dysfunction, DNA repair deficits, and RNA splicing errors—into a unified framework. The pharmacological agent P7C3-A20 offers a precision tool to repair this metabolic engine, utilizing the body's own salvage pathways to restore homeostasis without the risks of unregulated supplementation.

While the path to a pharmacy shelf remains long and fraught with clinical hurdles, the implications are profound. If the human brain retains the same latent capacity for repair seen in these mice, Alzheimer's Disease may eventually be reclassified from a terminal sentence to a manageable, and perhaps reversible, metabolic condition. The era of "Metabolic Resurrection" in neurology may have just begun.

#### **Works cited**

1. New study shows Alzheimer’s disease can be reversed to achieve full neurological recovery—not just prevented or slowed—in animal models, accessed December 26, 2025, [https://case.edu/news/new-study-shows-alzheimers-disease-can-be-reversed-achieve-full-neurological-recovery-not-just-prevented-or-slowed-animal-models](https://case.edu/news/new-study-shows-alzheimers-disease-can-be-reversed-achieve-full-neurological-recovery-not-just-prevented-or-slowed-animal-models)  
2. Study Shows Alzheimer's Disease Can Be Reversed in Animal Models \- UH Newsroom, accessed December 26, 2025, [https://news.uhhospitals.org/news-releases/articles/2025/12/study-shows-alzheimers-disease-can-be-reversed-in-animal-models](https://news.uhhospitals.org/news-releases/articles/2025/12/study-shows-alzheimers-disease-can-be-reversed-in-animal-models)  
3. Alzheimer's disease can be reversed in animal models? Study | Hacker News, accessed December 26, 2025, [https://news.ycombinator.com/item?id=46384919](https://news.ycombinator.com/item?id=46384919)  
4. NAD+ in Alzheimer's Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo \- NIH, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8369418/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8369418/)  
5. NAD+ and NADH in brain functions, brain diseases and brain aging \- PubMed \- NIH, accessed December 26, 2025, [https://pubmed.ncbi.nlm.nih.gov/17127427/](https://pubmed.ncbi.nlm.nih.gov/17127427/)  
6. Scientists achieve full neurological recovery from Alzheimer's in mice by restoring metabolic balance, accessed December 26, 2025, [https://www.psypost.org/scientists-achieve-full-neurological-recovery-from-alzheimers-in-mice-by-restoring-metabolic-balance/](https://www.psypost.org/scientists-achieve-full-neurological-recovery-from-alzheimers-in-mice-by-restoring-metabolic-balance/)  
7. Restoring brain energy balance reverses Alzheimer's disease in mouse models, accessed December 26, 2025, [https://www.news-medical.net/news/20251223/Restoring-brain-energy-balance-reverses-Alzheimere28099s-disease-in-mouse-models.aspx](https://www.news-medical.net/news/20251223/Restoring-brain-energy-balance-reverses-Alzheimere28099s-disease-in-mouse-models.aspx)  
8. Scientists reverse Alzheimer's in mice and restore memory | ScienceDaily, accessed December 26, 2025, [https://www.sciencedaily.com/releases/2025/12/251224032354.htm](https://www.sciencedaily.com/releases/2025/12/251224032354.htm)  
9. P7C3-A20 treatment one year after TBI in mice repairs the blood–brain barrier, arrests chronic neurodegeneration, and restores cognition \- PubMed Central, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7959512/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7959512/)  
10. P7C3 Neuroprotective Chemicals Function by Activating the Rate-limiting Enzyme in NAD Salvage \- PubMed Central, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4163014/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4163014/)  
11. UT Southwestern researchers discover novel class of NAMPT activators for neurodegenerative disease; Calico enters into exclusive collaboration with 2M to develop UTSW technology, accessed December 26, 2025, [https://www.calicolabs.com/press/ut-southwestern-researchers-discover-novel-class-of-nampt-activators-for-neurodegenerative-disease-calico-enters-into-exclusive-collaboration-with-2m-to-develop-utsw-technology/](https://www.calicolabs.com/press/ut-southwestern-researchers-discover-novel-class-of-nampt-activators-for-neurodegenerative-disease-calico-enters-into-exclusive-collaboration-with-2m-to-develop-utsw-technology/)  
12. Neurotherapeutic Capacity of P7C3 Agents for the Treatment of Traumatic Brain Injury \- PMC \- PubMed Central, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6309509/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6309509/)  
13. P7C3 Ameliorates Bone Loss by Inhibiting Osteoclast Differentiation and Promoting Osteogenesis | JBMR Plus | Oxford Academic, accessed December 26, 2025, [https://academic.oup.com/jbmrplus/article/7/12/e10811/7612358](https://academic.oup.com/jbmrplus/article/7/12/e10811/7612358)  
14. Google's stealthy Calico inks an R\&D deal for new compounds aimed at neurodegeneration, accessed December 26, 2025, [https://www.fiercebiotech.com/biotech/google-s-stealthy-calico-inks-an-r-d-deal-for-new-compounds-aimed-at-neurodegeneration](https://www.fiercebiotech.com/biotech/google-s-stealthy-calico-inks-an-r-d-deal-for-new-compounds-aimed-at-neurodegeneration)  
15. AbbVie-partnered Calico unveils first licensing deal \- PMLiVE, accessed December 26, 2025, [https://pmlive.com/pharma\_news/abbvie-partnered\_calico\_unveils\_first\_licensing\_deal\_598548/](https://pmlive.com/pharma_news/abbvie-partnered_calico_unveils_first_licensing_deal_598548/)  
16. Pathobiochemistry of Aging and Neurodegeneration: Deregulation of NAD+ Metabolism in Brain Cells \- MDPI, accessed December 26, 2025, [https://www.mdpi.com/2218-273X/14/12/1556](https://www.mdpi.com/2218-273X/14/12/1556)  
17. NAD+ supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency | PNAS, accessed December 26, 2025, [https://www.pnas.org/doi/10.1073/pnas.1718819115](https://www.pnas.org/doi/10.1073/pnas.1718819115)  
18. Synthesis, Optimization, and Structure–Activity Relationships of Nicotinamide Phosphoribosyltransferase (NAMPT) Positive Allosteric Modulators (N-PAMs) | Journal of Medicinal Chemistry \- ACS Publications, accessed December 26, 2025, [https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c01406](https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c01406)  
19. The mechanism of nicotinamide phosphoribosyltransferase whereby positive allosteric modulation elevates cellular NAD \+ \- bioRxiv, accessed December 26, 2025, [https://www.biorxiv.org/content/10.1101/2022.10.21.513220v1.full-text](https://www.biorxiv.org/content/10.1101/2022.10.21.513220v1.full-text)  
20. Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death | Journal of Medicinal Chemistry \- ACS Publications, accessed December 26, 2025, [https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c02112](https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c02112)  
21. P7C3-A20 Attenuates Microglial Inflammation and Brain Injury after ICH through Activating the NAD+/Sirt3 Pathway \- PubMed Central, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9936507/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9936507/)  
22. NAD \+ reverses Alzheimer's neurological deficits via regulating differential alternative RNA splicing of EVA1C \- PubMed, accessed December 26, 2025, [https://pubmed.ncbi.nlm.nih.gov/41202143/](https://pubmed.ncbi.nlm.nih.gov/41202143/)  
23. NAD+ Revives Memory In Alzheimer's Models \- Psychiatrist.com, accessed December 26, 2025, [https://www.psychiatrist.com/news/nad-revives-memory-in-alzheimers-models/](https://www.psychiatrist.com/news/nad-revives-memory-in-alzheimers-models/)  
24. Edwin Vázquez-Rosa's research works | Case Western Reserve University and other places, accessed December 26, 2025, [https://www.researchgate.net/scientific-contributions/Edwin-Vazquez-Rosa-59103994](https://www.researchgate.net/scientific-contributions/Edwin-Vazquez-Rosa-59103994)  
25. Metabolic stress and age drive inflammation and cognitive decline in mice and humans, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11923576/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11923576/)  
26. NAD+ improves cognitive function and reduces neuroinflammation by ameliorating mitochondrial damage and decreasing ROS production in chronic cerebral hypoperfusion models through Sirt1/PGC-1α pathway \- PMC \- PubMed Central, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8444613/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444613/)  
27. Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and their preclinical neuroprotective activity \- PubMed Central, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9160276/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9160276/)  
28. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment \- PubMed Central, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10828186/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10828186/)  
29. Pathway linked to slower aging also fuels brain cancer, accessed December 26, 2025, [https://siteman.wustl.edu/pathway-linked-slower-aging-also-fuels-brain-cancer/](https://siteman.wustl.edu/pathway-linked-slower-aging-also-fuels-brain-cancer/)  
30. Fueling genome maintenance: On the versatile roles of NAD+ in preserving DNA integrity, accessed December 26, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9194868/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9194868/)  
31. Targeting NAD+ metabolism: dual roles in cancer treatment \- Frontiers, accessed December 26, 2025, [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1269896/full](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1269896/full)  
32. Study Reveals NR Slows Liver Cancer Progression in Mice \- NAD.com, accessed December 26, 2025, [https://www.nad.com/news/nad-precursor-liver-cancer-progression](https://www.nad.com/news/nad-precursor-liver-cancer-progression)  
33. Nicotinamide Riboside Shows Effects on Hippocampal Features but Not Improved Memory, accessed December 26, 2025, [https://www.neurologylive.com/view/nicotinamide-riboside-shows-effects-hippocampal-features-not-improved-memory](https://www.neurologylive.com/view/nicotinamide-riboside-shows-effects-hippocampal-features-not-improved-memory)  
34. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment \- PubMed, accessed December 26, 2025, [https://pubmed.ncbi.nlm.nih.gov/37994989/](https://pubmed.ncbi.nlm.nih.gov/37994989/)  
35. Antioxidants for ALS · Recruiting Participants for Phase Phase 2 Clinical Trial 2025 | Power, accessed December 26, 2025, [https://www.withpower.com/trial/phase-3-amyotrophic-lateral-sclerosis-9-2020-f5285](https://www.withpower.com/trial/phase-3-amyotrophic-lateral-sclerosis-9-2020-f5285)  
36. Study Details | NCT04244630 | Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial | ClinicalTrials.gov, accessed December 26, 2025, [https://www.clinicaltrials.gov/study/NCT04244630](https://www.clinicaltrials.gov/study/NCT04244630)  
37. P7C3 Suppresses Neuroinflammation and Protects Retinal Ganglion Cells of Rats from Optic Nerve Crush | IOVS, accessed December 26, 2025, [https://iovs.arvojournals.org/article.aspx?articleid=2655096](https://iovs.arvojournals.org/article.aspx?articleid=2655096)  
38. Andrew Pieper, MD, PhD | Harrington Discovery Institute at University Hospitals, accessed December 26, 2025, [https://www.harringtondiscovery.org/about/meet-our-team/andrew-pieper-md-phd](https://www.harringtondiscovery.org/about/meet-our-team/andrew-pieper-md-phd)